NCT06924606 2026-02-06
Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Allist Pharmaceuticals, Inc.